Can I Take Rhodiola with Farxiga (Dapagliflozin)?

What Rhodiola Rosea Actually Does in the Body

Rhodiola rosea is an adaptogenic herb historically used in Scandinavian and Russian traditional medicine to reduce fatigue and support stress resilience. Its primary bioactive compounds, rosavin and salidroside, modulate the hypothalamic-pituitary-adrenal (HPA) axis and influence several neurotransmitter systems.

Mechanism of Action

Salidroside activates AMP-activated protein kinase (AMPK) in preclinical models, a pathway that also plays a role in glucose uptake and insulin sensitivity [1]. Rhodiola extracts have demonstrated weak inhibition of monoamine oxidase B (MAO-B) in vitro, which increases synaptic dopamine and, to a lesser extent, serotonin availability [2]. This MAOI-like property is what drives most interaction screening flags.

Metabolic Effects Worth Noting

A 2012 randomized controlled trial (N=60) published in Phytomedicine found that Rhodiola rosea extract (SHR-5, 340 mg/day) significantly reduced cortisol response to stress compared to placebo over 28 days [3]. Cortisol directly opposes insulin action, so lowering it could theoretically amplify the glucose-lowering effects of medications like dapagliflozin. An animal study in Molecular Medicine Reports showed salidroside improved insulin sensitivity and reduced fasting blood glucose in diabetic rat models by 18% over 8 weeks [4].

These effects are modest in humans at standard supplement doses (200 to 600 mg/day of standardized extract). They do not rival pharmaceutical glucose-lowering agents. But they are not zero.

How Dapagliflozin Works (and Where Overlap Could Occur)

Dapagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule, causing the kidneys to excrete approximately 50 to 80 grams of glucose daily [5]. The FDA approved it for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2020, and for chronic kidney disease in 2021.

Glucose-Lowering and Volume Effects

In the DAPA-HF trial (N=4,744), dapagliflozin 10 mg reduced HbA1c by roughly 0.2% even in patients without diabetes, alongside meaningful reductions in cardiovascular death and heart failure hospitalization [6]. The drug also produces a mild osmotic diuresis, lowering systolic blood pressure by 3 to 5 mmHg on average [7].

Metabolic Pathway

Dapagliflozin is primarily metabolized by uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to an inactive glucuronide metabolite [5]. CYP3A4 plays a minor role. This is relevant because most herb-drug interaction concerns center on CYP450 inhibition, and rhodiola's known effects on CYP enzymes are minimal at standard doses.

Pharmacokinetic Interaction Analysis: Is There a Metabolic Conflict?

The short answer: probably not at clinically relevant doses. The longer answer requires examining three enzyme families.

UGT1A9 and Rhodiola

Dapagliflozin depends on UGT1A9 for clearance. No published data show that rhodiola rosavins or salidroside meaningfully inhibit UGT1A9 in human liver microsomes. A 2019 in vitro study in Drug Metabolism and Disposition evaluated several botanical supplements for UGT inhibition and did not include rhodiola among significant inhibitors [8]. This absence of signal is not the same as proof of safety, but it lowers pharmacokinetic concern substantially.

CYP3A4 Considerations

Rhodiola has shown weak CYP3A4 induction in one in vitro study using human hepatocytes, but the effect was not replicated at physiologically achievable concentrations [9]. Since CYP3A4 accounts for only a minor fraction of dapagliflozin metabolism, even moderate CYP3A4 induction would not meaningfully change dapagliflozin plasma levels. The FDA prescribing information for Farxiga does not list CYP3A4 inducers as clinically significant interactors [5].

P-glycoprotein Transport

Dapagliflozin is a substrate of P-glycoprotein (P-gp). Rhodiola extracts have shown variable effects on P-gp in preclinical assays, with one study in European Journal of Drug Metabolism and Pharmacokinetics reporting mild P-gp inhibition by salidroside at high concentrations [10]. At standard oral rhodiola doses, intestinal salidroside concentrations are unlikely to reach inhibitory thresholds. This interaction remains theoretical.

Pharmacodynamic Interaction Analysis: Where the Real Questions Live

Even without a metabolic collision, two drugs can interact if their downstream effects overlap or oppose each other. Three pharmacodynamic domains deserve attention here.

Additive Hypoglycemia Risk

Dapagliflozin alone carries low hypoglycemia risk in patients not taking sulfonylureas or insulin [5]. Rhodiola's modest glucose-lowering effect through AMPK activation and cortisol reduction could add a small incremental reduction. For most patients on dapagliflozin monotherapy, this is unlikely to cause clinically significant hypoglycemia. For patients stacking dapagliflozin with metformin, a sulfonylurea, or insulin, the additional glucose-lowering contribution of rhodiola may tip the balance enough to warrant closer monitoring.

A practical threshold: if a patient's fasting glucose already runs below 90 mg/dL on dapagliflozin, adding rhodiola warrants 2 weeks of daily glucose checks.

Blood Pressure and Volume Status

Dapagliflozin produces mild volume contraction through glycosuria-driven osmotic diuresis [7]. Rhodiola has been associated with modest blood-pressure reductions in stressed populations, likely mediated through cortisol and catecholamine modulation [3]. The combination could theoretically lower blood pressure more than either agent alone.

Patients at highest risk: those already on antihypertensives, older adults (65+), and anyone with baseline orthostatic hypotension. The DAPA-CKD trial (N=4,304) reported volume depletion events in 5.9% of the dapagliflozin group versus 4.2% with placebo [11]. Adding any agent that further reduces blood pressure or volume warrants awareness.

Serotonergic and MAOI-Like Activity

Rhodiola's weak MAO-B inhibition is the property that triggers most interaction database flags [2]. This is relevant primarily when patients also take SSRIs, SNRIs, tramadol, or other serotonergic medications. Dapagliflozin has no serotonergic activity. The MAOI concern with rhodiola does not create a direct interaction with Farxiga, but it creates a three-way risk if a patient takes all three: dapagliflozin, rhodiola, and an SSRI.

The Natural Medicines Comprehensive Database rates rhodiola's interaction potential with SGLT2 inhibitors as "insufficient evidence to rate" rather than "known interaction" [12]. This is the honest state of the data.

What the Interaction Databases Say

Major drug interaction databases handle this pair differently because direct evidence is absent.

Database Ratings as of 2026

The Lexicomp and Micromedex databases do not list a specific dapagliflozin-rhodiola interaction monograph. The Natural Medicines database flags rhodiola for "theoretical" interactions with diabetes medications as a class, based on its glucose-lowering preclinical data, but does not single out SGLT2 inhibitors [12]. The Mayo Clinic drug interaction checker does not return a result for this specific combination.

What "No Listed Interaction" Actually Means

Absence of evidence is not evidence of absence. The lack of a formal interaction entry means no clinical events have been reported to the FDA MedWatch system or published in case reports specific to this pair. It does not mean the combination has been studied and found safe. This distinction matters.

According to a 2020 systematic review in JAMA Internal Medicine, approximately 73% of adults taking prescription medications also use at least one dietary supplement, yet fewer than 30% of common supplement-drug pairs have been evaluated in formal interaction studies [13].

Monitoring Recommendations for Patients Taking Both

If you and your prescriber decide that co-administration is reasonable, the following monitoring approach is prudent for the first 4 to 6 weeks.

Glucose Monitoring

Check fasting blood glucose at least 3 times per week for the first 2 weeks after adding rhodiola. If values remain stable (fasting glucose >80 mg/dL), reduce to weekly checks. Patients on combination antidiabetic therapy (dapagliflozin plus sulfonylurea or insulin) should monitor more frequently.

Blood Pressure and Hydration

Measure seated blood pressure at the same time each day for 2 weeks. Flag any systolic reading below 100 mmHg or any dizziness on standing. Maintain adequate fluid intake, at least 2 liters daily, to offset dapagliflozin's diuretic effect.

Symptoms to Report

Contact your prescriber if you experience lightheadedness, unusual fatigue, persistent nausea, or signs of ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing) regardless of blood glucose level. Euglycemic diabetic ketoacidosis (euDKA) is a known rare complication of SGLT2 inhibitors, occurring at a rate of approximately 0.1% in clinical trials [5]. While rhodiola has no known ketogenic effect, any additional metabolic variable warrants vigilance.

When to Separate Doses

No evidence-based dose-separation window exists for this pair. As a general precaution with herbal supplements and prescription medications, taking them 2 hours apart reduces the chance of absorption-phase interactions at the intestinal level. Take dapagliflozin in the morning as recommended by the prescribing information. Rhodiola is typically taken in the morning or early afternoon (it may interfere with sleep if taken late). Spacing them by 2 hours within the morning is reasonable.

Who Should Avoid This Combination Entirely

Not every patient faces the same risk profile. Some groups should err on the side of avoiding rhodiola while taking dapagliflozin.

Higher-Risk Populations

Patients with eGFR <30 mL/min/1.73 m² are already at increased risk for volume depletion and electrolyte disturbances on dapagliflozin. Adding an adaptogen with blood-pressure-lowering potential is inadvisable without nephrologist input. Patients with a history of euglycemic DKA should minimize variables that could obscure early symptoms.

Drug-Stacking Scenarios

Patients taking dapagliflozin alongside insulin or sulfonylureas face meaningful additive hypoglycemia risk. Adding rhodiola introduces a third glucose-lowering input. The same applies to patients on three or more antihypertensives: stacking another blood-pressure-lowering agent, even a mild one, increases fall risk, particularly in adults over 65.

Pregnancy and Lactation

Dapagliflozin is not recommended during the second and third trimesters of pregnancy based on animal data showing adverse renal effects [5]. Rhodiola lacks adequate human safety data in pregnancy. Neither agent should be used in pregnant or nursing patients without explicit medical direction.

If You Are Already Taking Both

Many patients begin supplements before discussing them with a prescriber. If you have been taking rhodiola alongside dapagliflozin without adverse effects, that is useful personal data. Do not abruptly stop either agent without medical guidance.

Steps to formalize the combination: bring the rhodiola product (with its label showing standardization and dose) to your next appointment. Ask your prescriber to document it in your medication list. Request baseline labs including a comprehensive metabolic panel (CMP), fasting glucose, and blood pressure. Repeat labs in 6 to 8 weeks to confirm stability.

If your prescriber advises discontinuation of rhodiola, taper over 1 to 2 weeks rather than stopping abruptly, as withdrawal-like fatigue has been anecdotally reported with chronic rhodiola use, though formal withdrawal studies are lacking.

Quality and Standardization Concerns with Rhodiola Products

The rhodiola supplement market has documented quality-control problems that compound interaction uncertainty.

Adulteration Risk

A 2019 analysis published in HerbalGram by the American Botanical Council tested 39 rhodiola products and found that 25% contained no detectable rhodiola DNA, instead containing cheaper substitutes such as Rhodiola crenulata or other species with different alkaloid profiles [14]. Patients who think they are taking Rhodiola rosea may be ingesting a different plant with different pharmacological properties.

Standardization Variability

Legitimate Rhodiola rosea products are typically standardized to 3% rosavins and 1% salidroside, reflecting the natural ratio in the root. Products deviating from this ratio may deliver unpredictable pharmacological effects. The United States Pharmacopeia (USP) has published a monograph for Rhodiola rosea, but third-party verification (USP, NSF, or ConsumerLab seal) remains uncommon among rhodiola supplements.

This quality variability means that even a well-studied interaction profile would be hard to apply uniformly across products. Patients should choose third-party tested rhodiola extracts and maintain consistent brand use if co-administering with prescription medications.